An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers

Erin A. Mcclure, Nathaniel L. Baker, Cassandra Gipson-Reichardt, Matthew J. Carpenter, Amanda P. Roper, Brett E. Froeliger, Peter W. Kalivas, Kevin M. Gray

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Varenicline (VAR) has demonstrated superior efficacy over other smoking cessation pharmacotherapies, though 50-60% of those treated do maintain abstinence. Some preclinical findings suggest that new nicotine dependence pharmacotherapies should target the glutamatergic system, given its demonstrated role in addiction. Attention has been given to N-acetylcysteine (NAC), which appears to restore normal glutamate signaling in animal models. It is possible that NAC and VAR may work in concert to promote abstinence at higher rates than with either medication alone. Objective: To demonstrate the feasibility and safety of co-administering NAC and VAR in nicotine-dependent participants. Methods: Participants (n=19) were daily cigarette smokers, and did not need to be seeking treatment. They received 4 weeks of open-label treatment with NAC (1200mg twice daily) and VAR (1mg twice daily, following titration) and were assessed weekly for adverse events (AEs), smoking, craving and withdrawal. Results: Sixteen participants reported a total of 40 AEs, and most were mild (88%). The most commonly reported AE was nausea (15%). Medication adherence, assessed via self-reports and pill counts, was excellent (98%). Exploratory analyses showed reductions in cigarettes per day, though point prevalence abstinence at the end of the study was low. Conclusions: These preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers. AEs were consistent with those typically reported for VAR and NAC. These data support future efficacy research on NAC and VAR for smoking cessation.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalAmerican Journal of Drug and Alcohol Abuse
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Acetylcysteine
Tobacco Products
Smoking Cessation
Safety
Drug Therapy
Tobacco Use Disorder
Medication Adherence
Varenicline
Nicotine
Self Report
Nausea
Glutamic Acid
Animal Models
Smoking
Therapeutics
Research

Keywords

  • N-acetylcysteine
  • Pharmacotherapy
  • Safety
  • Smoking cessation
  • Tolerability
  • Varenicline

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. / Mcclure, Erin A.; Baker, Nathaniel L.; Gipson-Reichardt, Cassandra; Carpenter, Matthew J.; Roper, Amanda P.; Froeliger, Brett E.; Kalivas, Peter W.; Gray, Kevin M.

In: American Journal of Drug and Alcohol Abuse, Vol. 41, No. 1, 01.01.2015, p. 52-56.

Research output: Contribution to journalArticle

Mcclure, Erin A. ; Baker, Nathaniel L. ; Gipson-Reichardt, Cassandra ; Carpenter, Matthew J. ; Roper, Amanda P. ; Froeliger, Brett E. ; Kalivas, Peter W. ; Gray, Kevin M. / An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. In: American Journal of Drug and Alcohol Abuse. 2015 ; Vol. 41, No. 1. pp. 52-56.
@article{2d497a05dea549359678d980f5ec432b,
title = "An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers",
abstract = "Background: Varenicline (VAR) has demonstrated superior efficacy over other smoking cessation pharmacotherapies, though 50-60{\%} of those treated do maintain abstinence. Some preclinical findings suggest that new nicotine dependence pharmacotherapies should target the glutamatergic system, given its demonstrated role in addiction. Attention has been given to N-acetylcysteine (NAC), which appears to restore normal glutamate signaling in animal models. It is possible that NAC and VAR may work in concert to promote abstinence at higher rates than with either medication alone. Objective: To demonstrate the feasibility and safety of co-administering NAC and VAR in nicotine-dependent participants. Methods: Participants (n=19) were daily cigarette smokers, and did not need to be seeking treatment. They received 4 weeks of open-label treatment with NAC (1200mg twice daily) and VAR (1mg twice daily, following titration) and were assessed weekly for adverse events (AEs), smoking, craving and withdrawal. Results: Sixteen participants reported a total of 40 AEs, and most were mild (88{\%}). The most commonly reported AE was nausea (15{\%}). Medication adherence, assessed via self-reports and pill counts, was excellent (98{\%}). Exploratory analyses showed reductions in cigarettes per day, though point prevalence abstinence at the end of the study was low. Conclusions: These preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers. AEs were consistent with those typically reported for VAR and NAC. These data support future efficacy research on NAC and VAR for smoking cessation.",
keywords = "N-acetylcysteine, Pharmacotherapy, Safety, Smoking cessation, Tolerability, Varenicline",
author = "Mcclure, {Erin A.} and Baker, {Nathaniel L.} and Cassandra Gipson-Reichardt and Carpenter, {Matthew J.} and Roper, {Amanda P.} and Froeliger, {Brett E.} and Kalivas, {Peter W.} and Gray, {Kevin M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/00952990.2014.933839",
language = "English (US)",
volume = "41",
pages = "52--56",
journal = "American Journal of Drug and Alcohol Abuse",
issn = "0095-2990",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers

AU - Mcclure, Erin A.

AU - Baker, Nathaniel L.

AU - Gipson-Reichardt, Cassandra

AU - Carpenter, Matthew J.

AU - Roper, Amanda P.

AU - Froeliger, Brett E.

AU - Kalivas, Peter W.

AU - Gray, Kevin M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Varenicline (VAR) has demonstrated superior efficacy over other smoking cessation pharmacotherapies, though 50-60% of those treated do maintain abstinence. Some preclinical findings suggest that new nicotine dependence pharmacotherapies should target the glutamatergic system, given its demonstrated role in addiction. Attention has been given to N-acetylcysteine (NAC), which appears to restore normal glutamate signaling in animal models. It is possible that NAC and VAR may work in concert to promote abstinence at higher rates than with either medication alone. Objective: To demonstrate the feasibility and safety of co-administering NAC and VAR in nicotine-dependent participants. Methods: Participants (n=19) were daily cigarette smokers, and did not need to be seeking treatment. They received 4 weeks of open-label treatment with NAC (1200mg twice daily) and VAR (1mg twice daily, following titration) and were assessed weekly for adverse events (AEs), smoking, craving and withdrawal. Results: Sixteen participants reported a total of 40 AEs, and most were mild (88%). The most commonly reported AE was nausea (15%). Medication adherence, assessed via self-reports and pill counts, was excellent (98%). Exploratory analyses showed reductions in cigarettes per day, though point prevalence abstinence at the end of the study was low. Conclusions: These preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers. AEs were consistent with those typically reported for VAR and NAC. These data support future efficacy research on NAC and VAR for smoking cessation.

AB - Background: Varenicline (VAR) has demonstrated superior efficacy over other smoking cessation pharmacotherapies, though 50-60% of those treated do maintain abstinence. Some preclinical findings suggest that new nicotine dependence pharmacotherapies should target the glutamatergic system, given its demonstrated role in addiction. Attention has been given to N-acetylcysteine (NAC), which appears to restore normal glutamate signaling in animal models. It is possible that NAC and VAR may work in concert to promote abstinence at higher rates than with either medication alone. Objective: To demonstrate the feasibility and safety of co-administering NAC and VAR in nicotine-dependent participants. Methods: Participants (n=19) were daily cigarette smokers, and did not need to be seeking treatment. They received 4 weeks of open-label treatment with NAC (1200mg twice daily) and VAR (1mg twice daily, following titration) and were assessed weekly for adverse events (AEs), smoking, craving and withdrawal. Results: Sixteen participants reported a total of 40 AEs, and most were mild (88%). The most commonly reported AE was nausea (15%). Medication adherence, assessed via self-reports and pill counts, was excellent (98%). Exploratory analyses showed reductions in cigarettes per day, though point prevalence abstinence at the end of the study was low. Conclusions: These preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers. AEs were consistent with those typically reported for VAR and NAC. These data support future efficacy research on NAC and VAR for smoking cessation.

KW - N-acetylcysteine

KW - Pharmacotherapy

KW - Safety

KW - Smoking cessation

KW - Tolerability

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=84917695097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917695097&partnerID=8YFLogxK

U2 - 10.3109/00952990.2014.933839

DO - 10.3109/00952990.2014.933839

M3 - Article

C2 - 25062287

AN - SCOPUS:84917695097

VL - 41

SP - 52

EP - 56

JO - American Journal of Drug and Alcohol Abuse

JF - American Journal of Drug and Alcohol Abuse

SN - 0095-2990

IS - 1

ER -